Solution for infusion (in a solution of sodium chloride 0.9%).
Bottle 100 ml.
Infectious and inflammatory diseases caused by microorganisms sensitive to ofloxacin: – respiratory tract infections (bronchitis, pneumonia)
– ENT organs (sinusitis, otitis media, tracheitis / except for pneumococcal infections)
skin infections – infections of bones and joints
– infectious and inflammatory diseases of the abdominal cavity (including biliary tract infections
– infections of the kidneys (pyelonephritis), urinary tract infections (cystitis, urethritis)
– infections of the pelvic organs ( ndometrit, salpingitis, oophoritis, cervicitis, parametritis, prostatitis) and genital (colpitis, orchitis, epididymitis)
– prevention of infections in patients with impaired immune status (including neutropenia).
Hypersensitivity, glucose-6-phosphate dehydrogenase deficiency, epilepsy (including a history), decreased seizure threshold (including after a head injury, stroke or inflammatory processes in the central nervous system, before 18) years (until the growth of the skeleton is completed), pregnancy, lactation, tendon lesions with previous treatment with fluoroquinolones.
Not a drug of choice for pneumococcal pneumonia.
Not indicated for the treatment of acute tonsillitis.
It is not recommended to be exposed to sunlight or irradiation with ultraviolet rays (mercury-quartz lamps, solarium).
In case of side effects from the central nervous system, allergic reactions, pseudomembranous colitis, drug withdrawal is necessary. With pseudomembranous colitis, confirmed colonoscopically and / or histologically, oral administration of vancomycin and metronidazole is indicated.
It should be borne in mind that with the use of Ofloxacin, rarely occurring tendonitis can lead to rupture of tendons (mainly the Achilles tendon),
especially in elderly patients. In case of signs of tendonitis, it is necessary to immediately stop treatment, immobilize the Achilles tendon and consult an orthopedist.
Ethanol should not be consumed during treatment.
When using the drug, women are not recommended to use hygienic tampons due to the increased risk of thrush.
Against the background of treatment, the course of myasthenia gravis, frequent porphyria attacks in predisposed patients are possible.
May lead to false negative results in the bacteriological diagnosis of tuberculosis (prevents the release of Mycobacterium tuberculosis).
In patients with impaired hepatic or renal function, plasma monitoring of ofloxacin concentration is necessary. In severe renal and hepatic insufficiency, the risk of toxic effects increases.
During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.
Active ingredient: ofloxacin 2 g
Excipients: sodium chloride water for injection – up to 1 liter
Dosage and Administration
Intravenous drip. Doses are selected individually depending on the location and severity of the infection, as well as the sensitivity of microorganisms, the general condition of the patient, and liver and kidney function.
Intravenous drip is prescribed with a single dose of 200 mg, which is administered slowly over 30-60 minutes. When the patient’s condition improves, they are transferred to the oral administration of the drug in the same daily dose.
Urinary tract infections – 100 mg 1-2 times a day, kidney and genital infections – from 100 mg 2 times a day to 200 mg 2 times a day, respiratory tract infections, as well as ENT organs, infections of the skin and soft tissues , infections of bones and joints, infections of the abdominal cavity, bacterial enteritis, septic infections – 200 mg 2 times a day. If necessary, increase the dose to 400 mg 2 times a day.
For the prevention of infections in patients with a pronounced decrease in immunity –
400 mg – 600 mg / day.
With hemodialysis and peritoneal dialysis – 100 mg every 24 hours. The maximum daily dose for liver failure is 400 mg / day.
In patients with impaired renal function (with CC from 50 to 20 ml / min), a single dose should be 50% of the average recommended dose with a multiplicity of administration 2 times a day or a full single dose is administered 1 time per day. With CC less than 20 ml / min, a single initial dose is 200 mg, then 100 mg / day every other day.
Side effects of the digestive system: gastralgia, decreased appetite, nausea, vomiting, diarrhea, flatulence, abdominal pain, increased activity of hepatic transaminases, hyperbilirubinemia, cholestatic jaundice, pseudomembranous enterocolitis.
From the side of the nervous system: headache, dizziness, lack of movement, tremors, cramps, numbness and paresthesias of the limbs, intense dreams, nightmares, psychotic reactions, anxiety, agitation, phobias, depression, confusion, hallucinations, increased intracranial pressure.
From the musculoskeletal system: tendonitis, myalgia, arthralgia, tendosynovitis, tendon rupture.
On the part of the sensory organs: impaired color perception, diplopia, impaired taste, smell, hearing and balance.
From the cardiovascular system: tachycardia, collapse, lowering blood pressure (with a sharp decrease in blood pressure, administration is stopped).
Allergic reactions: skin rash, itching, urticaria, allergic pneumonitis, allergic nephritis, eosinophilia, fever, angioedema, bronchospasm erythema multiforme exudative (including Stevens-Johnson syndrome) and toxic epidermal necrolysis (Lyell syndrome), vasculitis, anaphylactic shock.
From the skin: spot hemorrhages (petechiae), bullous hemorrhagic dermatitis, papular rash with a crust, indicating vascular damage (vasculitis).
From the hemopoietic organs: leukopenia, agranulocytosis, anemia, thrombocytopenia, pancytopenia, hemolytic and aplastic anemia.
From the urinary system: acute interstitial nephritis, impaired renal function, hypercreatininemia, increased urea concentration.
Other: intestinal dysbiosis, superinfection, photosensitivity, hypoglycemia (in patients with diabetes mellitus), vaginitis.
Local reactions: pain, hyperemia at the injection site, thrombophlebitis.
Reduces clearance of theophylline by 25% (with simultaneous use, the dose of theophylline should be reduced).
Increases the concentration of glibenclamide in plasma. Cimetidine, furosemide, methotrexate and drugs that block tubular secretion increase the concentration of ofloxacin in the plasma.
When taken with vitamin K antagonists, it is necessary to monitor the state of the blood coagulation system.
When administered with a non-steroidal anti-inflammatory drug, nitroimidazole derivatives and methylxanthines, the risk of developing neurotoxic effects increases.
When given concomitantly with a glucocorticosteroid, the risk of tendon rupture increases, especially in the elderly.
When given with medicines, alkalizing urine (carbonic anhydrase inhibitors, citrates, sodium bicarbonate), the risk of crystalluria and nephrotoxic effects increases.
Compatible with the following infusion solutions: 0.9% sodium chloride solution, Ringer’s solution, 5% fructose solution, 5% dextrose solution.
Do not mix with heparin because of the risk of precipitation.
When used concurrently with fluoroquinolones, prolongation of QT.
Symptoms: dizziness, confusion, lethargy, disorientation, drowsiness, vomiting.
Treatment: symptomatic therapy.
In a dark place at 15 ° C to 25 ° C. Freezing is not allowed.
Terms leave through pharmacies
solution for infusions
Bronchitis, Vaginal infections, Skin infections, Sinusitis, Cystitis, Otitis media, Pneumonia, Pyelonephritis, Pharyngitis, Urinary tract infections
Possible product names
Ofloxacin / Oflo / 2mg / ml solution d / inf. 100ml fl. B (R)
Ofloxacin 2mg / ml 100ml
Ofloxacin solution d / inf. 0.2% vial 100ml Russia
Ofloxacin vials 2 mg / ml, 100 ml